CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

Bladder cancer (BC) and melanoma are amenable to immune checkpoint blockade (ICB) therapy, yet most patients with advanced/metastatic disease do not respond. CD122-targeted interleukin (IL)-2 can improve ICB efficacy, but mechanisms are unclear. We tested αPD-L1 and CD122-directed immunotherapy with...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ryan M Reyes, Chenghao Zhang, Yilun Deng, Niannian Ji, Neelam Mukherjee, Alvaro S Padron, Curtis A Clark, Robert S Svatek, Tyler J Curiel
Format:	article
Langue:	EN
Publié:	Taylor & Francis Group 2021
Sujets:	preclinical immunotherapy lymphocyte activation tumor microenvironment urinary tissue-specific microenvironment melanoma bladder cancer immune checkpoint blockade il-2 cd122 nk cells metastasis Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/6f57b3a6ecf3451ead7b6bb61c301abc
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

Documents similaires